Assignee
IDEC PHARMA CORP
US·40 granted patents·17 pending applications·7,193 citations·filing 1992–2004
Top patents by PatentIndex Score
57 records- 0199US5736137ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1993·Granted Apr 7, 1998·1.6k cites·6 claims
- 0298US6455043B1Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodyIDEC PHARMA CORP·Filed 1999·Granted Sep 24, 2002·351 cites·15 claims
- 0398US6399061B1Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jun 4, 2002·254 cites·7 claims
- 0498US5776456ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jul 7, 1998·527 cites·14 claims
- 0598US5693780ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Dec 2, 1997·485 cites·16 claims
- 0698US5658570ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Aug 19, 1997·695 cites·38 claims
- 0797US6682734B1Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jan 27, 2004·176 cites·13 claims
- 0897US6136310ARecombinant anti-CD4 antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Oct 24, 2000·186 cites·16 claims
- 0997US6113898AHuman B7.1-specific primatized antibodies and transfectomas expressing said antibodiesIDEC PHARMA CORP·Filed 1995·Granted Sep 5, 2000·207 cites·11 claims
- 1097US5811524ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1995·Granted Sep 22, 1998·205 cites·11 claims
- 1197US5750105ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted May 12, 1998·318 cites·10 claims
- 1296US6846476B2Treatment of B-cell associated diseasesIDEC PHARMA CORP·Filed 2001·Granted Jan 25, 2005·100 cites·12 claims
- 1396US6001358AHumanized antibodies to human gp39, compositions containing thereofIDEC PHARMA CORP·Filed 1995·Granted Dec 14, 1999·125 cites·12 claims
- 1496US5958765ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Sep 28, 1999·185 cites·28 claims
- 1596US5756096ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted May 26, 1998·175 cites·6 claims
- 1696US5681722ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Oct 28, 1997·158 cites·8 claims
- 1794US6159730AImpaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameIDEC PHARMA CORP·Filed 1999·Granted Dec 12, 2000·123 cites·27 claims
- 1894US5866125ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Feb 2, 1999·86 cites·5 claims
- 1993US6413777B1Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the sameIDEC PHARMA CORP·Filed 1999·Granted Jul 2, 2002·120 cites·6 claims
- 2093US6413771B1Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1999·Granted Jul 2, 2002·60 cites·7 claims
- 2193US5939068ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Aug 17, 1999·83 cites·7 claims
- 2293US5840298ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Nov 24, 1998·75 cites·11 claims
- 2391US5955364ANeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 1996·Granted Sep 21, 1999·63 cites·9 claims
- 2491US5830698AMethod for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the sameIDEC PHARMA CORP·Filed 1997·Granted Nov 3, 1998·76 cites·38 claims
- 2590US6011138AGamma-1 anti-human CD23 monoclonal antibodiesIDEC PHARMA CORP·Filed 1997·Granted Jan 4, 2000·93 cites·20 claims
- 2690US5733779AImpaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameIDEC PHARMA CORP·Filed 1995·Granted Mar 31, 1998·85 cites·30 claims
- 2790US5585103AInduction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1992·Granted Dec 17, 1996·97 cites·20 claims
- 2888US6841383B2Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the sameIDEC PHARMA CORP·Filed 2002·Granted Jan 11, 2005·17 cites·16 claims
- 2987US5695770AInduction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1995·Granted Dec 9, 1997·74 cites·9 claims
- 3086US5709860AInduction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1994·Granted Jan 20, 1998·73 cites·23 claims
- 3185US5648267AImpaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameIDEC PHARMA CORP·Filed 1993·Granted Jul 15, 1997·82 cites·10 claims
- 3284US6270769B1Induction of cytotoxic T-lymphocyte responsesIDEC PHARMA CORP·Filed 1995·Granted Aug 7, 2001·61 cites·35 claims
- 3384US5998144AMethod for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the sameIDEC PHARMA CORP·Filed 1998·Granted Dec 7, 1999·63 cites·45 claims
- 3480US6440418B1Methods of treating autoimmune diseases with gp39-specific antibodiesIDEC PHARMA CORP·Filed 1997·Granted Aug 27, 2002·36 cites·16 claims
- 3580US6207858B1Regioselective synthesis of DTPA derivativesIDEC PHARMA CORP·Filed 1999·Granted Mar 27, 2001·47 cites·29 claims
- 3673US6451284B1Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphyIDEC PHARMA CORP·Filed 2000·Granted Sep 17, 2002·11 cites·52 claims
- 3773US6017733AImpaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising sameIDEC PHARMA CORP·Filed 1998·Granted Jan 25, 2000·24 cites·10 claims
- 3860US2003021781A1Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 3959US2005112060A1Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combinationIDEC PHARMA CORP·Filed 2003·Application pending·0 cites
- 4058US6506383B1Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodiesIDEC PHARMA CORP·Filed 1999·Granted Jan 14, 2003·9 cites·27 claims
- 4158US2004258616A1Compositions and methods for treating cancer using IGSF9 and LIV-1IDEC PHARMA CORP·Filed 2004·Application pending·0 cites
- 4258US2004005323A1Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereofIDEC PHARMA CORP·Filed 2003·Application pending·0 cites
- 4357US2003206903A1Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibodyIDEC PHARMA CORP·Filed 2003·Application pending·0 cites
- 4457US2004213784A1Use of chimeric anti-CD20 antibody as in vitro or in vivo purging agent in patients receiving BMT or PBSC transplantIDEC PHARMA CORP·Filed 2004·Application pending·0 cites
- 4557US2003235533A1Prostate specific genes and the use thereof in design or therapeuticsIDEC PHARMA CORP·Filed 2003·Application pending·0 cites
- 4655US2003026804A1Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodyIDEC PHARMA CORP·Filed 2002·Application pending·0 cites
- 4753US2002128448A1Variant IgG3 Rituxan and therapeutic use thereofIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 4851US2002150580A1Recombinant antibodies for human therapyIDEC PHARMA CORP·Filed 2001·Application pending·0 cites
- 4950US2003180290A1Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapiesIDEC PHARMA CORP·Filed 2002·Application pending·0 cites
- 5049US2003157641A1Polycistronic expression of antibodiesIDEC PHARMA CORP·Filed 2002·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when IDEC PHARMA CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →